Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Reuters
Published Apr 01, 2024 11:54AM ET
Updated Apr 01, 2024 02:06PM ET
By Blake Brittain
(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson (NYSE:JNJ) schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine.
The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider.
A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."
A Teva spokesperson said the company was pleased with the decision and looks forward to "providing this important low-cost medication to patients as soon as possible."
Representatives for Viatris did not immediately respond to a request for comment on the decision.
J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales, according to a company report. It sued Teva and Mylan (NASDAQ:VTRS), which is now part of Viatris, for patent infringement over their proposed generic versions of the drug in 2018 and 2019, respectively.
U.S. District Judge Claire Cecchi determined in Teva's case in 2021 that it failed to prove that J&J's patent, covering a dosing regimen for Invega Sustenna, was invalid. Viatris agreed to be bound by Cecchi's decision in its case.
A three-judge Federal Circuit panel threw out Cecchi's decision on Monday and sent the case back to the New Jersey court. The appeals court said Teva may be able to prove that the patent was invalid because the dosing regimen would have been obvious to an ordinary person in the field.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.